Generic products of antiepileptic drugs (AEDs): Is it an issue?

Epilepsia

Volumn 48, Issue 10, 2007, Pages 1825-1832

  Bialer, Meir ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Generic products of antiepileptic drugs; Interchangeability; Prescribability; Switchability

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; GENERIC DRUG; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID;

AREA UNDER THE CURVE; BIOEQUIVALENCE; DRUG EFFICACY; DRUG MONITORING; DRUG QUALITY; DRUG SAFETY; DRUG SCREENING; DRUG SUBSTITUTION; FOOD AND DRUG ADMINISTRATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SEIZURE;

ANTICONVULSANTS; CHEMISTRY, PHARMACEUTICAL; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG TOLERANCE; DRUGS, GENERIC; EPILEPSY; HUMANS; PRESCRIPTIONS, DRUG; THERAPEUTIC EQUIVALENCY;

EID: 35148836175     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2007.01272.x     Document Type: Review

References (47)

1. American Medical Association 2002) Featured Report; Generic Drugs (A-02). http://www.ama.assn.org/ama/pub/category/print/15279.html (accessed May 1, 2007).
2. Andermann F, Duh MS, Gosselin A, Paradis PE 2007) Compulsory generic switches of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes Epilepsia 48 : 464 469.
3. Banahan BF, Bonnarens JK, Bentley JP 1998) Generic substitution of NTI drugs: issues for formulary committee consideration. Formulary 33 : 1082 1096.
4. Berg MJ 2007) What's the problem with generic antiepileptic drugs? Neurology 68 : 1245 1246.
5. Besag FMC 2000) Is generic prescribing acceptable in epilepsy? Drug Safety 23 : 173 182.
6. Bialer M, Yacobi A, Moros D, Levitt B, Houl J-M, Munsaka MS 1998a) Criteria to assess in vivo performance and bioequivalence of generic controlled release (CR) formulations of carbamazepine. Epilepsia 39 : 513 519.
7. Bialer M, Aracvi L, Sussan S, Volosov A, Yacobi A, Moros D, Levitt B, Laor A 1998b) Existing and new criteria for bioequivalence evaluation of controlled release (CR) products of carbamazepine. Epilepsy Res 32 : 371 378.
8. Bialer M, Levy RH, Perucca E 1998c) Does carbamazepine have a narrow therapeutic plasma concentration range? Ther Drug Monit 20 : 56 59.
9. Chen M-L 1997) Individual bioequivalence - a regulatory update. J Biopharm Stat 7 : 5 11.
10. Chen M-L, Lesko LK 2001) Individual bioequivalence revisited. Clin Pharmacokinet 40 : 701 706.
11. Chow S-C 1997) Guest editor's note: recent issues in bioequivalence trials. J Biopharm Stat 7 : 1 3.
12. Committee for Proprietary Medicinal Products (CPMP) of the European Agency Medicinal Evaluation Agency (EMEA) 2001) Note for guidance for the investigation of bioavailability and bioequivalence. July 26, EMEA. London.www.eudra.org.html (accessed May 1, 2007).
13. Crawford P, Feely M, Guberman A, Kramer G 2006) Are there potential problems with generic substitution of antiepileptic drug?: a review of issues. Seizure 15 : 165 176.
14. Endrenyi L, Amidon GL, Midha KK, Skelly JP 1998) Individual bioequivalence: attractive in principle, difficult in practice. Pharm Res 15 : 1321 1325.
15. Endrenyi L, Midha KK 1998) Individual bioequivalence - has it time come? European J Pharm Sci 6 : 271 277.
16. Guberman A, Corman C 2000) Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci 27 : 37 43.
17. Hauck WW, Anderson S 1997) Individual bioequivalence - a regulatory update. J Biopharm Stat 7 : 13 16.
18. Hauck WW, Hyslop T, Chen M-L, Williams RL, and the FDA Population/Individual Bioequivalence Working Group 2000) Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. Pharm Res 17 : 375 380.
19. Hauschke D, Steinijans VW 2000) The U.S. draft guidance regarding population and individual bioequivalence approaches: comments by a research-based pharmaceutical company. Stat Med 19 : 2769 2774.
20. Health Canada 2007) Recall of two valproic acid drugs, Depakine 500 mg and ratio-Valproic 500 mg. issued on May 11, 2007.
21. Heaney DC, Sander JW 2007) Antiepileptic drugs: genetic versus branded treatments. Lancet Neurol 6 : 465 468.
22. Jobst BC, Holmes GL 2004) Prescribing antiepileptic drugs: should patients be switched on the basis of cost? CNS Drugs 18 : 617 628.
23. Johannessen SI, Batino D, Berry DJ, Bialer M, Kramer G, Tomson T, Patsalos PN 2003) Therapeutics drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 25 : 347 363.
24. Karmer G, Dennig D, Schnidt D, Schmitz B, Stefan H, Steinoff BJ, Stefani U, Stodieck S 2005) Generika in der epilepsitherapie. Was ist zu beachten? Akt Neuerole 30 : 275 278.
25. Kramer G, Schneble H, Wolf P 2002) Ad-hoc-Kommission der Deutschen Sekton der Internationalen Liga Gegen Epilepsie. Risken der neuen Aut-idem-Regelung fur die Behandlung mit Antiepileptika. Akt Neuerol 29 : 115 122.
26. Kramer G, Steinhoff BJ, Feucht M, Pfafflin M, May TW 2007) Experience with generic drugs in epilepsy patients: an electronic survey of members of the German, Austrian and Swiss Branches of the ILAE. Epilepsia 48 : 609 611.
27. Lesser RP, Krauss G 2001) Buy some today: can generic be safely substituted for brand-name drugs? Neurology 57 : 571 573.
28. Levy G 1995) The clay feet of bioequivalence. J Pharm Pharmacol 47 : 975 977.
29. Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW 2007) Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 68 : 1249 1250.
30. Markus GM, McCormick J 2007) Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clin Ther 29 : 334 341.
31. Mayer T, May TW, Altenmuller D-M, Sandmann M, Wolf P 1999) Clinical problems with generic antiepileptic drugs. Clin Drug Invest 18 : 17 26.
32. Midha KK, Rawson MJ, Hunbbard JW 1997) Individual and average bioequivalence of highly variable drugs and drug products. J Pharm Sci 86 : 1193 1197.
33. Nightingale SL 2001) Therapeutic equivalence of generic drugs: letter to health practitioners. Available at : http://www.fda.gov/cder/news/nightentlett. htm. (last accessed May 1, 2007).
34. Nuwer MR 2001) Generic substitutions for antiepileptic drugs. Neurology 41 : 1165.
35. Office of Generic Drugs 2001) What are generic drugs? Available at http://www.fda.gov/cder/ogd/index/htm (accessed May 1, 2007).
36. Perucca E, Albani F, Capovilla G, Dalla Bernardina B, Michelucci R, Zaccara G 2006) Recommendation of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia 47 (Suppl 5 16 20.
37. Richens A 1997) Impact of generic substitution of anticonvulsants on the treatment of epilepsy. CNS Drugs 8 : 124 133.
38. Rowland M, Tozer T 1995) Clinical Pharmacokinetics, 3rd ed, Williams & Wilkins, Baltimore, pp. 406 411.
39. Sachdeo RC, Belendiuk G 1987) Generic versus branded carabmazepine. Lancet 1 : 1432.
40. Schall R, Luus HE 1993) On population and individual bioequivalence. Stat Med 12 : 1109 1124.
41. Wilder BJ, Leppik I, Hietpas TJ, Cloyd JC, Randinitis EJ, Cook J 2001) Effect of food on absorption of Dilanatin Kapseals and Mylan extended phenytoin sodium capsule. Neurology 57 : 582 589.
42. Williams RL, Chen M-L, Hauck WW 2002) Equivalence approaches. Clin Pharmacol Ther 72 : 229 237.
43. Wilner AN 2002) Physicians underestimate the frequency of generic carbamazepine substitution: results of a survey and review of the problem. Epilepsy Behav 3 : 522 525.
44. Wilner AN 2004) Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 5 : 995 998.
45. Wolf P 2006) Generic substitution in antiepileptic drug treatment. Fall Conference of the ILAE-Danish Chapter, Kolding, Denmark, October 6-7, 2006.
46. Wolf P 2007) Political campaign in Denmark. In Abstract Book from the 27th International Epilepsy Congress in Singapore, 8th - 12th July : pp. 8 9.
47. Zintzaras E 2005) Statistical aspects of bioequivalence testing between two medicinal products. Eur J Drug Metab Pharmacokinet 30 : 41 46.